Using Akt Inhibitors to Target HIV-1 Infected Macrophages
Author Information
Author(s): Pauline Chugh, Birgit Bradel-Tretheway, Carlos M. R. Monteiro-Filho, Vicente Planelles, Sanjay B. Maggirwar, Stephen Dewhurst, Kim Baek
Primary Institution: University of Rochester Medical Center
Hypothesis
Can PI3K/Akt inhibitors reduce HIV-1 production in infected macrophages?
Conclusion
PI3K/Akt inhibitors may serve as a novel therapy to reduce HIV-1 production from long-living infected macrophages.
Supporting Evidence
- HIV-1 infected macrophages have an extended lifespan and produce virus continuously.
- PI3K/Akt inhibitors significantly reduced HIV-1 production when combined with stress treatment.
- The study identified a mechanism by which HIV-1 infection reduces PTEN levels, enhancing cell survival.
Takeaway
Researchers found that certain drugs can help kill HIV-infected cells without hurting healthy ones, which could help treat HIV.
Methodology
The study used primary human macrophages infected with HIV-1 and treated them with PI3K/Akt inhibitors to assess viral production and cell death.
Potential Biases
Potential bias in the selection of cell lines and treatment conditions.
Limitations
The study primarily focused on in vitro models, which may not fully replicate in vivo conditions.
Participant Demographics
Primary human macrophages isolated from multiple blood donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website